NASDAQ:SXTP 60 Degrees Pharmaceuticals (SXTP) Stock Price, News & Analysis $0.97 -0.01 (-0.73%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$0.94 -0.03 (-2.94%) As of 10/9/2026 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsSEC Filings About 60 Degrees Pharmaceuticals Stock (NASDAQ:SXTP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SXTP alerts:Sign Up Key Stats Today's Range$0.91▼$1.0050-Day Range$0.85▼$1.4452-Week Range$0.84▼$8.62Volume41,141 shsAverage Volume240,529 shsMarket Capitalization$3.40 millionP/E RatioN/ADividend YieldN/APrice Target$13.85Consensus RatingHold Company Overview 60 Degrees Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for infectious and tropical diseases. The company’s lead product is Arakoda (tafenoquine), an oral antimalarial approved by the U.S. Food and Drug Administration for the prevention of malaria in adults. Arakoda is designed for use as a malaria-prophylaxis regimen before, during and after travel to areas where malaria is present. The product is marketed in the United States, and 60 Degrees Pharmaceuticals has also pursued opportunities to expand access through international partnerships and regulatory development. The company was founded in 2010 and is headquartered in Washington, D.C. In addition to its malaria business, 60 Degrees Pharmaceuticals has evaluated tafenoquine and related therapies for other infectious diseases, including babesiosis, an emerging tick-borne disease. Geoffrey Dow serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More 60 Degrees Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreSXTP MarketRank™: 60 Degrees Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus Rating60 Degrees Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside Potential60 Degrees Pharmaceuticals has a consensus price target of $13.85, representing about 1,334.6% upside from its current price of $0.97.Amount of Analyst Coverage60 Degrees Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about 60 Degrees Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 60 Degrees Pharmaceuticals are expected to grow in the coming year, from ($3.31) to ($2.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 60 Degrees Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 60 Degrees Pharmaceuticals is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about 60 Degrees Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.86% of the float of 60 Degrees Pharmaceuticals has been sold short.Short Interest Ratio / Days to Cover60 Degrees Pharmaceuticals has a short interest ratio ("days to cover") of 1.61, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in 60 Degrees Pharmaceuticals has recently decreased by 38.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield60 Degrees Pharmaceuticals does not currently pay a dividend.Dividend Growth60 Degrees Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.10 News Sentiment60 Degrees Pharmaceuticals has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for 60 Degrees Pharmaceuticals this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added 60 Degrees Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, 60 Degrees Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.68% of the stock of 60 Degrees Pharmaceuticals is held by insiders.Percentage Held by Institutions7.96% of the stock of 60 Degrees Pharmaceuticals is held by institutions.Read more about 60 Degrees Pharmaceuticals' insider trading history. Receive SXTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 60 Degrees Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SXTP Stock News Headlines60 Degrees Pharmaceuticals (NASDAQ:SXTP) Stock Price Down 0.9% - Time to Sell?October 8 at 2:21 AM | americanbankingnews.com60 Degrees To Unblind Babesiosis Study In January 2027; Plans FDA Meeting Following Interim ReviewOctober 7 at 5:05 AM | rttnews.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyDocket No. OP-1670 is drawing attention for what it reveals about the Federal Reserve's next move. Buried on page 84 is a plan that could expand oversight of checking accounts, purchases, and money transfers across the country. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what this document means and why it could roll out as soon as this summer.October 10 at 1:00 AM | Weiss Ratings (Ad)60 Degrees Pharmaceuticals sets January 2027 babesiosis data readout and plans FDA pre-sNDA meetingOctober 7 at 5:05 AM | msn.com60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDAOctober 6, 2026 | globenewswire.comBabesiosis Data Readout Today As 60 Degrees Pharmaceuticals Shares ClimbOctober 6, 2026 | rttnews.com60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TVOctober 2, 2026 | finance.yahoo.com60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader WebinarOctober 1, 2026 | globenewswire.comSee More Headlines SXTP Stock Analysis - Frequently Asked Questions How have SXTP shares performed this year? 60 Degrees Pharmaceuticals' stock was trading at $2.0332 on January 1st, 2026. Since then, SXTP shares have decreased by 52.5% and is now trading at $0.9654. How were 60 Degrees Pharmaceuticals' earnings last quarter? 60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) issued its earnings results on Friday, August, 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by $0.16. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.21 million. When did 60 Degrees Pharmaceuticals' stock split? Shares of 60 Degrees Pharmaceuticals reverse split on Tuesday, January 20th 2026.A 1-4 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 19th 2026. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. When did 60 Degrees Pharmaceuticals IPO? 60 Degrees Pharmaceuticals (SXTP) raised $7 million in an initial public offering on Wednesday, July 12th 2023. The company issued 1,400,000 shares at $5.30 per share. WallachBeth Capital LLC served as the underwriter for the IPO. How do I buy shares of 60 Degrees Pharmaceuticals? Shares of SXTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 60 Degrees Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that 60 Degrees Pharmaceuticals investors own include Recursion Pharmaceuticals (RXRX), Editas Medicine (EDIT), Pacific Biosciences of California (PACB), Tilray Brands (TLRY), Akanda (AKAN), Better Therapeutics (BTTX) and Honeywell International (HON). Company Calendar Last Earnings8/14/2026Today10/10/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (6m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 SXTP's financial health is in the Yellow zone, according to TradeSmith. SXTP has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SXTP CIK1946563 Web60degreespharma.com Phone202-327-5422FaxN/AEmployees3Year Founded2010Price Target and Rating Average Price Target for 60 Degrees Pharmaceuticals$13.85 High Price Target$24.00 Low Price Target$3.70 Potential Upside/Downside+1,334.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($4.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.36 million Net Margins-650.21% Pretax Margin-650.62% Return on EquityN/A Return on Assets-136.81% Debt Debt-to-Equity RatioN/A Current Ratio2.32 Quick Ratio1.78 Sales & Book Value Annual Sales$1.11 million Price / Sales3.06 Cash FlowN/A Price / Cash FlowN/A Book Value($5.85) per share Price / Book-0.17Miscellaneous Outstanding Shares3,517,000Free Float3,458,000Market Cap$3.40 million OptionableNot Optionable Beta2.40 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:SXTP) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredMy next big call (under $1)On the first day of October, one of the biggest banks in the world changed its mind about Bitcoin. Citigroup r...Crypto 101 Media | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SXTP Stock Alerts